ライフサイエンスコーパス: fluorine-18-fluorodeoxyglucose

1 ough positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18)F-FDG) has a major i

2 al (IB) routes and imaged sequentially using fluorine-18 fluorodeoxyglucose ((18)FDG) uptake as a non

3 Histograms of administered activity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iod

4 aging, and positron emission tomography with fluorine 18 fluorodeoxyglucose and novel tracers.

5 s, positron emission tomography imaging with fluorine-18-fluorodeoxyglucose, and cardiac magnetic res

6 ermined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumo

7 patients (20.7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median

8 CT scans is feasible and may be helpful when fluorine 18 fluorodeoxyglucose-avid masses that are not

9 Fluorine-18-fluorodeoxyglucose detected unsuspected meta

10 analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is

11 lculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small

12 PET with the labeled glucose analogue fluorine 18 fluorodeoxyglucose (FDG) is a relatively rec

13 lly suspected underwent clinically indicated fluorine 18 fluorodeoxyglucose (FDG) PET/CT and, immedia

14 he correlation between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission t

15 Purpose To assess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

16 cal-pathologic nodal status with use of four fluorine 18 fluorodeoxyglucose (FDG) positron emission t

17 It has been reported that fluorine 18 fluorodeoxyglucose (FDG) positron emission t

18 baseline magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission t

19 Fluorine 18 fluorodeoxyglucose (FDG) positron emission t

20 ively compare the sensitivity of a dedicated fluorine 18 fluorodeoxyglucose (FDG) positron emission t

21 luate the positive predictive value (PPV) of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

22 aging technique in body imaging is currently fluorine 18 fluorodeoxyglucose (FDG) positron emission t

23 he established patterns of hypometabolism on fluorine 18 fluorodeoxyglucose (FDG) positron emission t

24 trinsic contrast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission t

25 ss significant (P < .05) differences between fluorine 18 fluorodeoxyglucose (FDG) uptake of benign le

26 Fluorine 18 fluorodeoxyglucose (FDG) was mixed with diff

27 acilitate future direct correlations between fluorine 18 fluorodeoxyglucose (FDG)-avid colonic lesion

28 ts suspected of having abdominal or thoracic fluorine 18 fluorodeoxyglucose (FDG)-positive lesions un

29 and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG).

30 y (PET) using nitrogen-13 (N-13) ammonia and fluorine-18 fluorodeoxyglucose (FDG) for imaging of perf

31 pectively investigated the value of PET with fluorine-18 fluorodeoxyglucose (FDG) for preoperative ch

32 hat positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may be useful for d

33 , and two underwent gallium scintigraphy and fluorine-18 fluorodeoxyglucose (FDG) positron emission t

34 a marker for tissue viability with regional fluorine-18 fluorodeoxyglucose (FDG) uptake in patients

35 There seems to be emerging roles for fluorine-18 fluorodeoxyglucose (FDG)-PET, laparoscopic s

36 We visually compared fluorine-18-fluorodeoxyglucose (FDG)-PET images to radio

37 rves (TACs) from mouse PET studies done with fluorine-18-fluorodeoxyglucose (FDG).

38 Fluorine-18-fluorodeoxyglucose imaging was more accurate

39 olving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to involve a

40 nt contrast material-enhanced MR imaging and fluorine 18 fluorodeoxyglucose PEM in randomized order;

41 y (PET) and coregistered computed tomography/fluorine 18 fluorodeoxyglucose PET are used primarily in

42 rials and Methods Between 2010 and 2013, 219 fluorine 18 fluorodeoxyglucose PET examinations were per

43 etail methods for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to

44 l of 30 lesions were evaluated at (18)F- FDG fluorine 18 fluorodeoxyglucose PET/CT and (18)F- FPPRGD2

45 trointestinal malignancies underwent two FDG fluorine 18 fluorodeoxyglucose PET/CT examinations withi

46 Two hundred eighty-two fluorine 18 fluorodeoxyglucose PET/CT studies in 75 pedi

47 background is recommended in multicenter FDG fluorine 18 fluorodeoxyglucose PET/CT studies on the bas

48 phic (CT) and (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose ) PET/CT examinations wer

49 Fluorine 18 fluorodeoxyglucose positron emission tomogra

50 ndmark finding relied on the use of clinical fluorine 18 fluorodeoxyglucose positron emission tomogra

51 d 20 nonsmoking control subjects underwent 2 fluorine 18-fluorodeoxyglucose positron emission tomogra

52 The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomogra

53 Fluorine-18 fluorodeoxyglucose positron emission tomogra

54 Functional metabolic imaging through fluorine-18 fluorodeoxyglucose positron emission tomogra

55 erapy with both computed tomography (CT) and fluorine-18 fluorodeoxyglucose positron emission tomogra

56 magnetic resonance imaging and angiography, fluorine-18-fluorodeoxyglucose positron emission tomogra

57 es after injection, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

58 2.3) at 60 minutes, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu